Medico Remedies Ltd Pays Penalties to BSE and NSE Following Alleged Listing Non-Compliance
Medico Remedies Ltd., a manufacturer of pharmaceutical formulations, confirmed it has settled penalties levied by both the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) related to alleged non-compliance with listing regulations.The company received a Show Cause Notice (SoP) from both exchanges on February 20, 2026, concerning alleged non-compliance with Regulation 6(1) of the Listing Regulations. The respective waiver applications filed by the company were subsequently rejected by BSE and NSE.
The financial details and timeline of the action are as follows:
| Authority | Date of Notice | Alleged Violation | Penalty Amount | Waiver Rejection Date |
|---|---|---|---|---|
| NSE | February 20, 2026 | Non-compliance of Listing Regulations | Rs. 63,720/- | April 10, 2026 |
| BSE | February 20, 2026 | Non-compliance of Listing Regulations | Rs. 63,720/- | March 5, 2026 |
According to the company, the requisite SoP fines were paid with both BSE and NSE on February 24, 2026. The firm stated that as of February 18, 2026, it is compliant with Regulation 6 (1) of the SEBI (LODR) Regulations, 2015.
In assessing the impact of the penalties and the non-compliance issue, Medico Remedies Ltd. stated there is no material impact on the company's financials, operations, or other activities.
Medico Remedies Ltd. is identified as a World Health Organisation Factory and a WHO-GMP, ISO 9001-2015 & Govt. Recognised Star Export House, specializing in pharmaceutical formulations.
MEDICO Stock Price Movement
Today, Medico Remedies Limited shares edged higher to close at ₹39.62, gaining 1.07% on the close. The stock settled on a volume of 442,130 shares, signaling robust post-market interest.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.